Matheux F, Le Grand R, Rousseau V, De Maeyer E, Dormont D, Lauret E
CEA, Service de Neurovirologie (DSV/DRM), CRSSA, Institut Paris Sud sur les Cytokines, Fontenay aux Roses, France.
Hum Gene Ther. 1999 Feb 10;10(3):429-40. doi: 10.1089/10430349950018878.
We are developing a method of gene therapy of HIV infection based on the low constitutive expression of an interferon beta (IFN-beta) gene in HIV target cells. Herein we report the first step in the development of a relevant animal model, provided by the macaque (Macaca fascicularis) infected with a pathogenic SIVmac251 isolate. To avoid the possibility of in vivo rejection of macaque lymphocytes expressing Hu IFN-beta, we have PCR-amplified and sequenced the Ma IFN-beta-coding sequence, and placed it under the control of a PstI-NruI 0.6-kb fragment of the murine H-2Kb gene promoter in the MFG-K(b)MaIFNbeta retroviral vector. Lymphocytic CEMX174 cells, transduced by coculture on packaging cells with this construct, harbored a mean of 0.07 to 1.2 copies of the IFN-beta transgene per cell, and were characterized by an IFN production ranging from 75 to 750 units per 5 x 10(5) cells per 3 days. The IFN-beta-transduced populations displayed an enhanced resistance against the pathogenic SIVmac251 isolate. Control experiments showed that the enhanced resistance could not be ascribed to the Ma IFN-beta released during the 3 days of coculture by the packaging cells, or to the mere transduction with a retroviral vector. Macaque lymphocytes transduced by the MFG-K(b)MaIFNbeta retroviral vector by coculture on packaging cells, acquired a mean number of IFN-beta transgene copies per cell ranging from 0.03 to 0.1. Such transduction led to the release of IFN-beta into the culture medium, ranging from 10 to 20 units per 5 x 10(5) cells per 3 days. This increased the anti-SIV resistance of the lymphocytes, as demonstrated by a decreased p27 antigen release into the culture medium, without affecting lymphocyte proliferation.
我们正在基于HIV靶细胞中干扰素β(IFN-β)基因的低组成性表达来开发一种HIV感染的基因治疗方法。在此,我们报告了相关动物模型开发的第一步,该模型由感染致病性SIVmac251分离株的猕猴(食蟹猴)提供。为避免表达人IFN-β的猕猴淋巴细胞在体内被排斥的可能性,我们对猴IFN-β编码序列进行了PCR扩增和测序,并将其置于MFG-K(b)MaIFNbeta逆转录病毒载体中鼠H-2Kb基因启动子的PstI-NruI 0.6 kb片段的控制之下。通过与该构建体在包装细胞上共培养转导的淋巴细胞性CEMX174细胞,每个细胞平均含有0.07至1.2个IFN-β转基因拷贝,其特征在于每3天每5×10(5)个细胞产生75至750单位的IFN。转导了IFN-β的群体对致病性SIVmac251分离株表现出增强的抗性。对照实验表明,增强的抗性不能归因于包装细胞在共培养3天期间释放的猴IFN-β,也不能归因于单纯用逆转录病毒载体进行转导。通过在包装细胞上共培养由MFG-K(b)MaIFNbeta逆转录病毒载体转导的猕猴淋巴细胞,每个细胞获得的IFN-β转基因拷贝平均数为0.03至0.1。这种转导导致IFN-β释放到培养基中,每3天每5×10(5)个细胞释放10至20单位。这增加了淋巴细胞的抗SIV抗性,这通过培养基中p27抗原释放的减少得以证明,而不影响淋巴细胞增殖。